| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Polycystic Ovary Syndrome | 27 | 2024 | 65 | 6.500 |
Why?
|
| Cardiovascular Diseases | 31 | 2023 | 366 | 5.520 |
Why?
|
| Women's Health | 24 | 2024 | 59 | 3.550 |
Why?
|
| Postmenopause | 35 | 2024 | 83 | 3.540 |
Why?
|
| Dyslipidemias | 10 | 2021 | 32 | 2.880 |
Why?
|
| Estrogen Replacement Therapy | 17 | 2022 | 42 | 2.740 |
Why?
|
| Female | 133 | 2024 | 15156 | 2.500 |
Why?
|
| Lipids | 15 | 2021 | 208 | 2.420 |
Why?
|
| Hyperlipidemias | 8 | 2022 | 37 | 2.300 |
Why?
|
| Humans | 145 | 2025 | 28121 | 1.950 |
Why?
|
| Risk Factors | 55 | 2024 | 2084 | 1.920 |
Why?
|
| Infertility, Female | 9 | 2024 | 43 | 1.860 |
Why?
|
| Hypertension | 9 | 2023 | 309 | 1.840 |
Why?
|
| Insulin Resistance | 10 | 2022 | 176 | 1.830 |
Why?
|
| Menopause | 11 | 2024 | 30 | 1.820 |
Why?
|
| Androgens | 16 | 2022 | 47 | 1.790 |
Why?
|
| Pregnancy | 31 | 2024 | 1181 | 1.750 |
Why?
|
| Ovulation Induction | 9 | 2024 | 34 | 1.640 |
Why?
|
| Obesity | 19 | 2022 | 668 | 1.530 |
Why?
|
| Body Mass Index | 18 | 2024 | 398 | 1.390 |
Why?
|
| Metabolic Syndrome | 8 | 2024 | 78 | 1.250 |
Why?
|
| Pregnancy Complications, Cardiovascular | 3 | 2021 | 15 | 1.130 |
Why?
|
| Pre-Eclampsia | 3 | 2023 | 49 | 1.080 |
Why?
|
| Coronary Disease | 6 | 2023 | 119 | 1.070 |
Why?
|
| Disease Management | 3 | 2015 | 88 | 0.930 |
Why?
|
| Live Birth | 8 | 2024 | 40 | 0.930 |
Why?
|
| Thyroid Gland | 2 | 2024 | 32 | 0.930 |
Why?
|
| Metformin | 2 | 2020 | 36 | 0.930 |
Why?
|
| Preventive Health Services | 2 | 2021 | 16 | 0.870 |
Why?
|
| Perimenopause | 2 | 2014 | 6 | 0.830 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 5 | 2018 | 75 | 0.820 |
Why?
|
| Luteinizing Hormone | 2 | 2022 | 57 | 0.800 |
Why?
|
| Middle Aged | 38 | 2024 | 7164 | 0.800 |
Why?
|
| Lipoproteins | 11 | 2022 | 99 | 0.800 |
Why?
|
| Follicle Stimulating Hormone | 2 | 2022 | 71 | 0.790 |
Why?
|
| Hirsutism | 10 | 2005 | 18 | 0.780 |
Why?
|
| Proprotein Convertases | 1 | 2022 | 11 | 0.780 |
Why?
|
| Evidence-Based Medicine | 3 | 2014 | 145 | 0.780 |
Why?
|
| Estrogens | 8 | 2022 | 56 | 0.760 |
Why?
|
| Prospective Studies | 22 | 2024 | 1249 | 0.760 |
Why?
|
| Salpingo-oophorectomy | 1 | 2021 | 3 | 0.730 |
Why?
|
| Cholesterol, LDL | 9 | 2022 | 65 | 0.720 |
Why?
|
| Gynecology | 5 | 2020 | 58 | 0.720 |
Why?
|
| Aged | 31 | 2024 | 5416 | 0.710 |
Why?
|
| Adult | 40 | 2024 | 7757 | 0.710 |
Why?
|
| Thyroxine | 1 | 2020 | 11 | 0.700 |
Why?
|
| Premature Birth | 4 | 2024 | 50 | 0.680 |
Why?
|
| Randomized Controlled Trials as Topic | 6 | 2022 | 385 | 0.670 |
Why?
|
| Osteoporosis | 2 | 2013 | 63 | 0.650 |
Why?
|
| Aging | 4 | 2020 | 976 | 0.640 |
Why?
|
| Biomarkers | 10 | 2024 | 755 | 0.640 |
Why?
|
| United States | 19 | 2024 | 2149 | 0.640 |
Why?
|
| Endometriosis | 8 | 1996 | 19 | 0.630 |
Why?
|
| Precision Medicine | 2 | 2022 | 77 | 0.610 |
Why?
|
| Infertility, Male | 4 | 2020 | 23 | 0.600 |
Why?
|
| Estrogens, Conjugated (USP) | 7 | 2022 | 14 | 0.600 |
Why?
|
| Hot Flashes | 3 | 2020 | 6 | 0.570 |
Why?
|
| Carotid Arteries | 2 | 2012 | 54 | 0.540 |
Why?
|
| Risk Assessment | 9 | 2022 | 611 | 0.540 |
Why?
|
| Life Style | 5 | 2022 | 88 | 0.530 |
Why?
|
| Pregnancy Outcome | 6 | 2024 | 131 | 0.520 |
Why?
|
| Coronary Vessels | 2 | 2012 | 152 | 0.510 |
Why?
|
| Autoantibodies | 7 | 2024 | 474 | 0.510 |
Why?
|
| Mass Screening | 4 | 2022 | 152 | 0.500 |
Why?
|
| Research Report | 1 | 2016 | 23 | 0.500 |
Why?
|
| Risk | 6 | 2021 | 136 | 0.490 |
Why?
|
| Goals | 2 | 2014 | 34 | 0.470 |
Why?
|
| Prenatal Care | 1 | 2015 | 40 | 0.470 |
Why?
|
| Models, Biological | 3 | 2014 | 465 | 0.470 |
Why?
|
| Pregnancy Complications | 4 | 2021 | 111 | 0.460 |
Why?
|
| Fetus | 1 | 2015 | 77 | 0.460 |
Why?
|
| Parity | 2 | 2024 | 50 | 0.460 |
Why?
|
| Practice Guidelines as Topic | 2 | 2013 | 242 | 0.450 |
Why?
|
| Infertility | 3 | 2022 | 35 | 0.450 |
Why?
|
| Endometrium | 7 | 1996 | 39 | 0.450 |
Why?
|
| Treatment Outcome | 12 | 2024 | 2380 | 0.450 |
Why?
|
| Insemination, Artificial | 4 | 2022 | 27 | 0.440 |
Why?
|
| Depression | 2 | 2019 | 215 | 0.440 |
Why?
|
| Progestins | 4 | 2019 | 10 | 0.430 |
Why?
|
| Triglycerides | 9 | 2022 | 120 | 0.420 |
Why?
|
| Hysterectomy | 3 | 2013 | 85 | 0.420 |
Why?
|
| Antihypertensive Agents | 3 | 2023 | 56 | 0.410 |
Why?
|
| Pelvic Floor | 1 | 2013 | 35 | 0.400 |
Why?
|
| Anticholesteremic Agents | 1 | 2012 | 13 | 0.400 |
Why?
|
| Muscles | 1 | 2013 | 73 | 0.400 |
Why?
|
| Hormones | 2 | 2012 | 43 | 0.400 |
Why?
|
| Pliability | 1 | 2012 | 6 | 0.390 |
Why?
|
| Urination Disorders | 1 | 2012 | 9 | 0.390 |
Why?
|
| Cystoscopy | 1 | 2012 | 16 | 0.390 |
Why?
|
| Risk Reduction Behavior | 4 | 2021 | 46 | 0.380 |
Why?
|
| Case-Control Studies | 6 | 2023 | 722 | 0.380 |
Why?
|
| Mortality | 3 | 2021 | 46 | 0.380 |
Why?
|
| Vascular Calcification | 1 | 2012 | 20 | 0.380 |
Why?
|
| Blood Pressure | 6 | 2022 | 355 | 0.380 |
Why?
|
| Ultrasonography | 1 | 2013 | 241 | 0.380 |
Why?
|
| Cohort Studies | 7 | 2022 | 886 | 0.370 |
Why?
|
| Autoimmunity | 2 | 2024 | 156 | 0.360 |
Why?
|
| Anxiety Disorders | 1 | 2011 | 59 | 0.360 |
Why?
|
| Coronary Artery Disease | 3 | 2012 | 217 | 0.360 |
Why?
|
| Research Design | 1 | 2012 | 182 | 0.360 |
Why?
|
| Perineum | 1 | 2011 | 14 | 0.360 |
Why?
|
| Anal Canal | 1 | 2011 | 19 | 0.360 |
Why?
|
| Aorta | 1 | 2012 | 124 | 0.350 |
Why?
|
| Digestive System Surgical Procedures | 1 | 2011 | 18 | 0.350 |
Why?
|
| Abortion, Spontaneous | 4 | 2024 | 17 | 0.350 |
Why?
|
| Calcium | 2 | 2020 | 235 | 0.350 |
Why?
|
| Evoked Potentials, Auditory, Brain Stem | 1 | 2010 | 12 | 0.330 |
Why?
|
| Diabetes Mellitus | 5 | 2022 | 215 | 0.330 |
Why?
|
| Pain | 1 | 2012 | 258 | 0.320 |
Why?
|
| Walking | 2 | 2021 | 135 | 0.310 |
Why?
|
| Heart Failure | 2 | 2022 | 247 | 0.310 |
Why?
|
| Cholesterol | 8 | 2022 | 200 | 0.310 |
Why?
|
| Luteal Phase | 2 | 2019 | 7 | 0.300 |
Why?
|
| Reproductive History | 3 | 2024 | 9 | 0.300 |
Why?
|
| Prenatal Exposure Delayed Effects | 1 | 2010 | 108 | 0.300 |
Why?
|
| Endometrial Neoplasms | 2 | 2022 | 189 | 0.300 |
Why?
|
| Thiazolidinediones | 1 | 2008 | 10 | 0.290 |
Why?
|
| Testosterone | 7 | 2019 | 70 | 0.280 |
Why?
|
| Progesterone | 2 | 2019 | 129 | 0.280 |
Why?
|
| Pregnancy Rate | 7 | 2024 | 49 | 0.280 |
Why?
|
| Longitudinal Studies | 4 | 2024 | 413 | 0.280 |
Why?
|
| Atherosclerosis | 4 | 2015 | 96 | 0.270 |
Why?
|
| Ovariectomy | 1 | 2007 | 53 | 0.270 |
Why?
|
| Arteriosclerosis | 3 | 1996 | 29 | 0.270 |
Why?
|
| Smoking | 2 | 2010 | 473 | 0.270 |
Why?
|
| Waist Circumference | 3 | 2021 | 20 | 0.260 |
Why?
|
| Infant, Newborn | 7 | 2024 | 873 | 0.260 |
Why?
|
| Prevalence | 5 | 2011 | 494 | 0.260 |
Why?
|
| Incidence | 6 | 2021 | 562 | 0.260 |
Why?
|
| Cholesterol, HDL | 7 | 2020 | 59 | 0.260 |
Why?
|
| Apolipoproteins | 4 | 2011 | 21 | 0.250 |
Why?
|
| Purines | 1 | 2025 | 17 | 0.250 |
Why?
|
| Receptors, Estrogen | 1 | 2005 | 43 | 0.240 |
Why?
|
| Health Knowledge, Attitudes, Practice | 2 | 2020 | 296 | 0.240 |
Why?
|
| Quality of Life | 3 | 2019 | 491 | 0.240 |
Why?
|
| Hair | 1 | 2005 | 15 | 0.240 |
Why?
|
| Uterine Neoplasms | 3 | 2017 | 71 | 0.240 |
Why?
|
| Thyrotropin | 1 | 2024 | 11 | 0.230 |
Why?
|
| Reproductive Health | 1 | 2024 | 6 | 0.230 |
Why?
|
| Menarche | 1 | 2024 | 8 | 0.230 |
Why?
|
| Neoplasms | 3 | 2025 | 818 | 0.220 |
Why?
|
| Glucose Intolerance | 3 | 2010 | 23 | 0.220 |
Why?
|
| Time Factors | 7 | 2020 | 1593 | 0.210 |
Why?
|
| Body Fat Distribution | 2 | 2022 | 15 | 0.210 |
Why?
|
| Male | 16 | 2025 | 13487 | 0.210 |
Why?
|
| Insulin | 7 | 2022 | 315 | 0.210 |
Why?
|
| Soybean Proteins | 1 | 2003 | 8 | 0.210 |
Why?
|
| Bone Resorption | 1 | 2003 | 23 | 0.200 |
Why?
|
| Subcutaneous Fat | 1 | 2023 | 17 | 0.200 |
Why?
|
| Cardiovascular Physiological Phenomena | 2 | 2009 | 23 | 0.200 |
Why?
|
| Medroxyprogesterone Acetate | 5 | 2022 | 18 | 0.200 |
Why?
|
| Insemination, Artificial, Homologous | 2 | 2020 | 4 | 0.200 |
Why?
|
| Estradiol | 3 | 2022 | 175 | 0.200 |
Why?
|
| Proprotein Convertase 9 | 1 | 2022 | 3 | 0.200 |
Why?
|
| Subtilisins | 1 | 2022 | 6 | 0.200 |
Why?
|
| Diabetes, Gestational | 1 | 2023 | 68 | 0.190 |
Why?
|
| Proteinuria | 1 | 2022 | 14 | 0.190 |
Why?
|
| Insemination | 2 | 2020 | 6 | 0.190 |
Why?
|
| Recreation | 1 | 2021 | 6 | 0.190 |
Why?
|
| Surveys and Questionnaires | 3 | 2019 | 969 | 0.190 |
Why?
|
| Decision Support Techniques | 1 | 2022 | 50 | 0.190 |
Why?
|
| Nurses | 1 | 2021 | 13 | 0.190 |
Why?
|
| Abortifacient Agents, Nonsteroidal | 1 | 2021 | 5 | 0.190 |
Why?
|
| Microvascular Angina | 1 | 2001 | 1 | 0.180 |
Why?
|
| Pregnancy, Ectopic | 1 | 2021 | 11 | 0.180 |
Why?
|
| Methotrexate | 1 | 2021 | 34 | 0.180 |
Why?
|
| Cross-Sectional Studies | 6 | 2021 | 968 | 0.180 |
Why?
|
| Watchful Waiting | 1 | 2021 | 18 | 0.180 |
Why?
|
| Eggs | 1 | 2021 | 1 | 0.180 |
Why?
|
| Placenta | 1 | 2022 | 75 | 0.180 |
Why?
|
| Cholesterol, Dietary | 1 | 2021 | 6 | 0.180 |
Why?
|
| Hormone Replacement Therapy | 1 | 2021 | 9 | 0.180 |
Why?
|
| Selective Estrogen Receptor Modulators | 1 | 2001 | 8 | 0.180 |
Why?
|
| Australia | 1 | 2021 | 39 | 0.180 |
Why?
|
| Hypertriglyceridemia | 1 | 2021 | 8 | 0.180 |
Why?
|
| Contraception | 1 | 2021 | 21 | 0.180 |
Why?
|
| Dehydroepiandrosterone | 5 | 1994 | 14 | 0.180 |
Why?
|
| Accelerometry | 1 | 2021 | 12 | 0.180 |
Why?
|
| Cause of Death | 1 | 2021 | 73 | 0.170 |
Why?
|
| Walking Speed | 1 | 2020 | 3 | 0.170 |
Why?
|
| Lipoprotein(a) | 1 | 2020 | 8 | 0.170 |
Why?
|
| Aortic Rupture | 1 | 2020 | 8 | 0.170 |
Why?
|
| Aortic Aneurysm, Abdominal | 1 | 2020 | 24 | 0.170 |
Why?
|
| Triple Negative Breast Neoplasms | 1 | 2021 | 36 | 0.170 |
Why?
|
| Hypolipidemic Agents | 2 | 2018 | 20 | 0.170 |
Why?
|
| Overweight | 1 | 2021 | 111 | 0.170 |
Why?
|
| Reproducibility of Results | 2 | 2013 | 773 | 0.170 |
Why?
|
| Ambulatory Care Facilities | 1 | 2020 | 54 | 0.170 |
Why?
|
| Weight Gain | 1 | 2020 | 74 | 0.170 |
Why?
|
| Colorectal Neoplasms | 1 | 2022 | 139 | 0.170 |
Why?
|
| Genital Diseases, Female | 1 | 2019 | 7 | 0.160 |
Why?
|
| Diabetes Mellitus, Type 2 | 3 | 2010 | 330 | 0.160 |
Why?
|
| Phenotype | 1 | 2022 | 679 | 0.160 |
Why?
|
| Chorionic Gonadotropin | 2 | 2021 | 22 | 0.160 |
Why?
|
| Erectile Dysfunction | 1 | 2019 | 15 | 0.160 |
Why?
|
| Spermatogenesis | 1 | 2019 | 11 | 0.160 |
Why?
|
| Clinical Trials as Topic | 2 | 2016 | 215 | 0.160 |
Why?
|
| Climacteric | 1 | 1998 | 1 | 0.150 |
Why?
|
| Breast Neoplasms | 2 | 2022 | 464 | 0.150 |
Why?
|
| National Institute of Child Health and Human Development (U.S.) | 1 | 2018 | 2 | 0.150 |
Why?
|
| Hypoglycemic Agents | 1 | 2020 | 108 | 0.150 |
Why?
|
| Ethics Committees, Research | 1 | 2018 | 6 | 0.150 |
Why?
|
| Primary Prevention | 1 | 1998 | 25 | 0.150 |
Why?
|
| Clinical Protocols | 1 | 2018 | 46 | 0.150 |
Why?
|
| Vitamin D | 2 | 2020 | 49 | 0.150 |
Why?
|
| China | 1 | 2018 | 61 | 0.150 |
Why?
|
| Societies, Medical | 2 | 2017 | 93 | 0.140 |
Why?
|
| Antioxidants | 1 | 2020 | 225 | 0.140 |
Why?
|
| Combined Modality Therapy | 2 | 2021 | 302 | 0.140 |
Why?
|
| Patient Care Team | 1 | 2017 | 66 | 0.140 |
Why?
|
| Pilot Projects | 2 | 2020 | 432 | 0.140 |
Why?
|
| Fertility Agents | 1 | 2017 | 2 | 0.140 |
Why?
|
| Leiomyoma | 1 | 2017 | 9 | 0.130 |
Why?
|
| Ovulation | 1 | 2017 | 28 | 0.130 |
Why?
|
| Anthropometry | 2 | 2014 | 94 | 0.130 |
Why?
|
| Adolescent | 6 | 2015 | 3123 | 0.130 |
Why?
|
| Fatty Acids, Omega-3 | 1 | 2016 | 35 | 0.130 |
Why?
|
| Aged, 80 and over | 5 | 2022 | 2021 | 0.120 |
Why?
|
| Patient Education as Topic | 1 | 2016 | 91 | 0.120 |
Why?
|
| Patient-Centered Care | 1 | 2015 | 30 | 0.120 |
Why?
|
| Regression Analysis | 2 | 2013 | 210 | 0.120 |
Why?
|
| Exercise | 4 | 2022 | 482 | 0.120 |
Why?
|
| Double-Blind Method | 6 | 2020 | 414 | 0.120 |
Why?
|
| Indians, North American | 3 | 2005 | 517 | 0.120 |
Why?
|
| Fertility | 3 | 2022 | 58 | 0.120 |
Why?
|
| Sex Characteristics | 1 | 2016 | 172 | 0.120 |
Why?
|
| Birth Rate | 1 | 2014 | 11 | 0.120 |
Why?
|
| Autoimmune Diseases | 1 | 2016 | 164 | 0.120 |
Why?
|
| Lipid Metabolism | 2 | 1996 | 133 | 0.120 |
Why?
|
| Ovarian Neoplasms | 1 | 2021 | 595 | 0.120 |
Why?
|
| Fertilization in Vitro | 1 | 2014 | 24 | 0.110 |
Why?
|
| Genetic Markers | 1 | 2014 | 93 | 0.110 |
Why?
|
| Odds Ratio | 2 | 2013 | 237 | 0.110 |
Why?
|
| Hyperinsulinism | 2 | 1995 | 16 | 0.110 |
Why?
|
| Placebos | 2 | 2013 | 47 | 0.110 |
Why?
|
| Single Parent | 1 | 1994 | 1 | 0.110 |
Why?
|
| Maternal Behavior | 1 | 1994 | 9 | 0.110 |
Why?
|
| Vitamins | 1 | 2013 | 23 | 0.110 |
Why?
|
| Bone Density Conservation Agents | 1 | 2013 | 18 | 0.110 |
Why?
|
| Intra-Abdominal Fat | 2 | 2024 | 21 | 0.110 |
Why?
|
| Motor Activity | 1 | 2014 | 147 | 0.110 |
Why?
|
| Analysis of Variance | 6 | 2014 | 390 | 0.100 |
Why?
|
| Age Factors | 3 | 2019 | 733 | 0.100 |
Why?
|
| Observer Variation | 1 | 2013 | 43 | 0.100 |
Why?
|
| Fluorescent Antibody Technique | 5 | 1993 | 112 | 0.100 |
Why?
|
| Hypercholesterolemia | 1 | 2012 | 18 | 0.100 |
Why?
|
| C-Reactive Protein | 3 | 2022 | 92 | 0.100 |
Why?
|
| Body Weight | 3 | 1998 | 250 | 0.100 |
Why?
|
| Bias | 1 | 2012 | 42 | 0.100 |
Why?
|
| Adiposity | 2 | 2024 | 94 | 0.100 |
Why?
|
| Health Behavior | 1 | 1994 | 156 | 0.100 |
Why?
|
| Imaging, Three-Dimensional | 1 | 2013 | 129 | 0.100 |
Why?
|
| Blood Glucose | 3 | 2004 | 311 | 0.100 |
Why?
|
| Complement Activation | 1 | 1992 | 25 | 0.100 |
Why?
|
| Lipase | 1 | 2011 | 10 | 0.100 |
Why?
|
| Carotid Intima-Media Thickness | 1 | 2011 | 10 | 0.090 |
Why?
|
| Endocrine System Diseases | 1 | 1991 | 5 | 0.090 |
Why?
|
| Immunoglobulin Fab Fragments | 1 | 1991 | 21 | 0.090 |
Why?
|
| Lipoproteins, LDL | 1 | 2011 | 36 | 0.090 |
Why?
|
| Ethinyl Estradiol | 1 | 1991 | 2 | 0.090 |
Why?
|
| Norethindrone | 1 | 1991 | 2 | 0.090 |
Why?
|
| Adaptation, Physiological | 1 | 1992 | 169 | 0.090 |
Why?
|
| Fertility Agents, Female | 2 | 2022 | 15 | 0.090 |
Why?
|
| Spironolactone | 1 | 1991 | 4 | 0.090 |
Why?
|
| Sex Factors | 2 | 2020 | 465 | 0.090 |
Why?
|
| Dietary Supplements | 1 | 2013 | 239 | 0.090 |
Why?
|
| Pain Measurement | 1 | 2012 | 166 | 0.090 |
Why?
|
| Weight Loss | 2 | 2022 | 81 | 0.090 |
Why?
|
| Immunoglobulin G | 2 | 1996 | 270 | 0.090 |
Why?
|
| Hyperandrogenism | 1 | 2011 | 11 | 0.090 |
Why?
|
| Antigens, Tumor-Associated, Carbohydrate | 1 | 1991 | 12 | 0.090 |
Why?
|
| Physician-Patient Relations | 1 | 2012 | 113 | 0.090 |
Why?
|
| Genital Neoplasms, Female | 1 | 1991 | 67 | 0.090 |
Why?
|
| Pregnancy in Diabetics | 1 | 2010 | 21 | 0.090 |
Why?
|
| Waist-Hip Ratio | 1 | 2010 | 9 | 0.080 |
Why?
|
| Sperm Count | 2 | 2020 | 17 | 0.080 |
Why?
|
| Carotid Artery Diseases | 2 | 2018 | 37 | 0.080 |
Why?
|
| Animals | 5 | 2025 | 10399 | 0.080 |
Why?
|
| Cotinine | 1 | 2010 | 45 | 0.080 |
Why?
|
| Child | 4 | 2020 | 2242 | 0.080 |
Why?
|
| Contraceptives, Oral | 2 | 1995 | 23 | 0.080 |
Why?
|
| Multicenter Studies as Topic | 2 | 2019 | 48 | 0.080 |
Why?
|
| Adrenal Glands | 2 | 1994 | 21 | 0.080 |
Why?
|
| Kidney | 1 | 2010 | 285 | 0.080 |
Why?
|
| Diabetes Complications | 2 | 2002 | 66 | 0.070 |
Why?
|
| Patient Satisfaction | 2 | 2021 | 97 | 0.070 |
Why?
|
| Adrenal Cortex | 1 | 1987 | 13 | 0.070 |
Why?
|
| Biomarkers, Tumor | 1 | 1991 | 406 | 0.070 |
Why?
|
| Vaginal Diseases | 1 | 2007 | 5 | 0.070 |
Why?
|
| Bone and Bones | 1 | 1987 | 75 | 0.070 |
Why?
|
| Purine-Nucleoside Phosphorylase | 1 | 2025 | 6 | 0.060 |
Why?
|
| Microtubules | 1 | 2025 | 91 | 0.060 |
Why?
|
| Follow-Up Studies | 1 | 2008 | 1014 | 0.060 |
Why?
|
| Iodide Peroxidase | 1 | 2024 | 10 | 0.060 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2025 | 270 | 0.060 |
Why?
|
| Abdominal Fat | 1 | 2024 | 17 | 0.060 |
Why?
|
| Social Class | 1 | 2024 | 81 | 0.050 |
Why?
|
| Body Composition | 2 | 2023 | 265 | 0.050 |
Why?
|
| Retrospective Studies | 2 | 2024 | 2557 | 0.050 |
Why?
|
| Stillbirth | 1 | 2023 | 15 | 0.050 |
Why?
|
| Term Birth | 1 | 2023 | 10 | 0.050 |
Why?
|
| Healthy Lifestyle | 1 | 2023 | 4 | 0.050 |
Why?
|
| Stromal Cells | 2 | 1994 | 61 | 0.050 |
Why?
|
| Milk Proteins | 1 | 2003 | 18 | 0.050 |
Why?
|
| Birth Weight | 1 | 2023 | 63 | 0.050 |
Why?
|
| Homeostasis | 1 | 2004 | 117 | 0.050 |
Why?
|
| Raloxifene Hydrochloride | 2 | 2000 | 8 | 0.050 |
Why?
|
| Tremor | 1 | 2022 | 1 | 0.050 |
Why?
|
| Arthralgia | 1 | 2022 | 7 | 0.050 |
Why?
|
| Dizziness | 1 | 2022 | 10 | 0.050 |
Why?
|
| Contraceptives, Oral, Combined | 1 | 1982 | 5 | 0.050 |
Why?
|
| Uterus | 1 | 2002 | 31 | 0.050 |
Why?
|
| Coitus | 1 | 2022 | 14 | 0.050 |
Why?
|
| Fertilization | 1 | 2022 | 9 | 0.050 |
Why?
|
| Maternal Age | 1 | 2022 | 25 | 0.050 |
Why?
|
| Analgesics | 1 | 2022 | 38 | 0.050 |
Why?
|
| Hand Strength | 1 | 2022 | 38 | 0.050 |
Why?
|
| Preconception Care | 1 | 2022 | 17 | 0.050 |
Why?
|
| Extremities | 1 | 2022 | 22 | 0.050 |
Why?
|
| Dilatation and Curettage | 1 | 2021 | 4 | 0.050 |
Why?
|
| Neoplasm Staging | 3 | 1991 | 478 | 0.050 |
Why?
|
| Uterine Hemorrhage | 1 | 2021 | 9 | 0.050 |
Why?
|
| Leptin | 1 | 2022 | 67 | 0.050 |
Why?
|
| Young Adult | 2 | 2022 | 2731 | 0.050 |
Why?
|
| Clinical Decision-Making | 1 | 2022 | 63 | 0.050 |
Why?
|
| Cell Line, Tumor | 1 | 2025 | 1324 | 0.050 |
Why?
|
| Fasting | 1 | 2022 | 81 | 0.050 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2022 | 77 | 0.050 |
Why?
|
| Stroke Volume | 1 | 2022 | 123 | 0.050 |
Why?
|
| Clomiphene | 1 | 2021 | 11 | 0.050 |
Why?
|
| Body Height | 1 | 2021 | 57 | 0.050 |
Why?
|
| Ultrasonography, Prenatal | 1 | 2021 | 36 | 0.050 |
Why?
|
| False Negative Reactions | 2 | 1991 | 24 | 0.050 |
Why?
|
| False Positive Reactions | 2 | 1991 | 30 | 0.050 |
Why?
|
| Proportional Hazards Models | 1 | 2022 | 226 | 0.040 |
Why?
|
| Aspirin | 1 | 2022 | 124 | 0.040 |
Why?
|
| Dehydroepiandrosterone Sulfate | 2 | 1992 | 5 | 0.040 |
Why?
|
| Insulin-Like Growth Factor I | 1 | 2003 | 301 | 0.040 |
Why?
|
| Blood Coagulation Factors | 2 | 1998 | 31 | 0.040 |
Why?
|
| Hospitalization | 1 | 2022 | 202 | 0.040 |
Why?
|
| Spermatozoa | 1 | 2020 | 33 | 0.040 |
Why?
|
| Feeding Behavior | 1 | 2021 | 102 | 0.040 |
Why?
|
| Homocysteine | 1 | 2000 | 29 | 0.040 |
Why?
|
| Medicare | 1 | 2020 | 121 | 0.040 |
Why?
|
| Obstetrics | 1 | 2020 | 49 | 0.040 |
Why?
|
| Poisson Distribution | 1 | 2019 | 7 | 0.040 |
Why?
|
| Causality | 1 | 2019 | 14 | 0.040 |
Why?
|
| Selection Bias | 1 | 2019 | 13 | 0.040 |
Why?
|
| Glucose Tolerance Test | 2 | 2002 | 60 | 0.040 |
Why?
|
| Longevity | 1 | 2021 | 134 | 0.040 |
Why?
|
| Semen Analysis | 1 | 2019 | 13 | 0.040 |
Why?
|
| Comorbidity | 1 | 2020 | 256 | 0.040 |
Why?
|
| Feasibility Studies | 1 | 2020 | 193 | 0.040 |
Why?
|
| Sperm Motility | 1 | 2019 | 15 | 0.040 |
Why?
|
| Endocrinologists | 1 | 2019 | 2 | 0.040 |
Why?
|
| Survival Analysis | 1 | 2020 | 289 | 0.040 |
Why?
|
| Osteoporosis, Postmenopausal | 1 | 1998 | 9 | 0.040 |
Why?
|
| Reproductive Medicine | 1 | 2018 | 4 | 0.040 |
Why?
|
| Medical History Taking | 1 | 1998 | 18 | 0.040 |
Why?
|
| Models, Theoretical | 1 | 2019 | 134 | 0.040 |
Why?
|
| Down-Regulation | 1 | 2019 | 198 | 0.040 |
Why?
|
| Estrogen Antagonists | 1 | 1998 | 16 | 0.040 |
Why?
|
| Physical Examination | 1 | 1998 | 51 | 0.040 |
Why?
|
| Prognosis | 1 | 2020 | 803 | 0.040 |
Why?
|
| Piperidines | 1 | 1998 | 48 | 0.040 |
Why?
|
| Guidelines as Topic | 1 | 2017 | 46 | 0.040 |
Why?
|
| Mice | 2 | 2025 | 4645 | 0.030 |
Why?
|
| Tumor Cells, Cultured | 3 | 1993 | 315 | 0.030 |
Why?
|
| Pregnancy Tests | 1 | 2017 | 1 | 0.030 |
Why?
|
| Carbonic Anhydrases | 1 | 1996 | 6 | 0.030 |
Why?
|
| Medical Oncology | 1 | 2017 | 94 | 0.030 |
Why?
|
| Peritoneal Cavity | 2 | 1993 | 13 | 0.030 |
Why?
|
| Americas | 1 | 2016 | 5 | 0.030 |
Why?
|
| Drug Therapy, Combination | 1 | 2017 | 207 | 0.030 |
Why?
|
| Cardiovascular System | 1 | 1996 | 39 | 0.030 |
Why?
|
| Lipoproteins, HDL | 2 | 1998 | 41 | 0.030 |
Why?
|
| Medication Adherence | 1 | 2016 | 47 | 0.030 |
Why?
|
| Government Agencies | 1 | 2015 | 5 | 0.030 |
Why?
|
| Apolipoproteins B | 1 | 2015 | 18 | 0.030 |
Why?
|
| Physicians | 1 | 2016 | 82 | 0.030 |
Why?
|
| Epithelial Cells | 2 | 1994 | 247 | 0.030 |
Why?
|
| Tumor Necrosis Factor-alpha | 2 | 1993 | 248 | 0.030 |
Why?
|
| Embryo Transfer | 1 | 2014 | 13 | 0.030 |
Why?
|
| Hydrocortisone | 2 | 1987 | 89 | 0.030 |
Why?
|
| Expert Testimony | 1 | 2014 | 7 | 0.030 |
Why?
|
| Chi-Square Distribution | 1 | 2014 | 145 | 0.030 |
Why?
|
| Predictive Value of Tests | 1 | 2016 | 475 | 0.030 |
Why?
|
| African Americans | 1 | 2017 | 350 | 0.030 |
Why?
|
| Immunohistochemistry | 2 | 1993 | 462 | 0.030 |
Why?
|
| Coculture Techniques | 1 | 1994 | 55 | 0.030 |
Why?
|
| Mucins | 1 | 1993 | 24 | 0.030 |
Why?
|
| Trachea | 1 | 1993 | 26 | 0.030 |
Why?
|
| Cervix Uteri | 1 | 1993 | 64 | 0.030 |
Why?
|
| Vulvar Diseases | 1 | 1993 | 1 | 0.030 |
Why?
|
| Acanthosis Nigricans | 1 | 1993 | 4 | 0.030 |
Why?
|
| Endothelium, Vascular | 1 | 1996 | 325 | 0.030 |
Why?
|
| Epitopes | 1 | 1993 | 179 | 0.030 |
Why?
|
| Fluorescein-5-isothiocyanate | 1 | 1992 | 17 | 0.020 |
Why?
|
| Cytoplasm | 1 | 1992 | 57 | 0.020 |
Why?
|
| Complement C3d | 1 | 1992 | 1 | 0.020 |
Why?
|
| CD55 Antigens | 1 | 1992 | 2 | 0.020 |
Why?
|
| Disease Progression | 1 | 2014 | 473 | 0.020 |
Why?
|
| Complement Inactivator Proteins | 1 | 1992 | 8 | 0.020 |
Why?
|
| Anovulation | 1 | 1992 | 10 | 0.020 |
Why?
|
| Complement Membrane Attack Complex | 1 | 1992 | 16 | 0.020 |
Why?
|
| Fluorescent Dyes | 1 | 1992 | 90 | 0.020 |
Why?
|
| Gonadal Steroid Hormones | 1 | 1992 | 24 | 0.020 |
Why?
|
| von Willebrand Factor | 1 | 1992 | 36 | 0.020 |
Why?
|
| Fibrinogen | 2 | 2004 | 50 | 0.020 |
Why?
|
| Metabolic Diseases | 1 | 2011 | 16 | 0.020 |
Why?
|
| Ovary | 1 | 1992 | 69 | 0.020 |
Why?
|
| Androstane-3,17-diol | 1 | 1991 | 9 | 0.020 |
Why?
|
| Consensus | 1 | 2011 | 75 | 0.020 |
Why?
|
| Antibody Formation | 1 | 1991 | 77 | 0.020 |
Why?
|
| Antibodies | 1 | 1992 | 124 | 0.020 |
Why?
|
| Staining and Labeling | 1 | 1991 | 69 | 0.020 |
Why?
|
| Radioimmunoassay | 1 | 2011 | 45 | 0.020 |
Why?
|
| Sex Hormone-Binding Globulin | 1 | 1990 | 4 | 0.020 |
Why?
|
| Acne Vulgaris | 1 | 1990 | 6 | 0.020 |
Why?
|
| Congenital Abnormalities | 1 | 2010 | 16 | 0.020 |
Why?
|
| Texas | 1 | 2010 | 135 | 0.020 |
Why?
|
| Kidney Diseases | 1 | 2010 | 59 | 0.020 |
Why?
|
| Cardiac Catheterization | 1 | 1990 | 113 | 0.020 |
Why?
|
| Menstrual Cycle | 1 | 1990 | 24 | 0.020 |
Why?
|
| Macrophages | 1 | 1991 | 296 | 0.020 |
Why?
|
| Cholesterol, VLDL | 1 | 1988 | 2 | 0.020 |
Why?
|
| Lipoproteins, VLDL | 1 | 1988 | 6 | 0.020 |
Why?
|
| Membrane Proteins | 1 | 1992 | 485 | 0.020 |
Why?
|
| Menstruation | 1 | 1985 | 9 | 0.020 |
Why?
|
| Gonadotropins | 1 | 1985 | 22 | 0.020 |
Why?
|
| Marital Status | 1 | 2005 | 16 | 0.020 |
Why?
|
| Educational Status | 1 | 2005 | 113 | 0.010 |
Why?
|
| Plasminogen Activator Inhibitor 1 | 1 | 2004 | 20 | 0.010 |
Why?
|
| Adrenocorticotropic Hormone | 1 | 1982 | 17 | 0.010 |
Why?
|
| Androstenedione | 1 | 1982 | 34 | 0.010 |
Why?
|
| Dexamethasone | 1 | 1982 | 63 | 0.010 |
Why?
|
| Progesterone Congeners | 1 | 1998 | 4 | 0.010 |
Why?
|
| Lipoproteins, HDL2 | 1 | 1998 | 1 | 0.010 |
Why?
|
| Isoenzymes | 1 | 1996 | 86 | 0.010 |
Why?
|
| Antibody Specificity | 1 | 1996 | 114 | 0.010 |
Why?
|
| Immunoblotting | 1 | 1996 | 123 | 0.010 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 1996 | 257 | 0.010 |
Why?
|
| Antibodies, Antinuclear | 1 | 1996 | 183 | 0.010 |
Why?
|
| Cattle | 1 | 1996 | 389 | 0.010 |
Why?
|
| Apolipoprotein A-I | 1 | 1994 | 38 | 0.010 |
Why?
|
| Epithelium | 1 | 1993 | 39 | 0.010 |
Why?
|
| Mice, Inbred BALB C | 1 | 1993 | 276 | 0.010 |
Why?
|
| Cell Adhesion | 1 | 1993 | 138 | 0.010 |
Why?
|
| Interleukin-1 | 1 | 1991 | 23 | 0.010 |
Why?
|
| Transforming Growth Factor alpha | 1 | 1991 | 7 | 0.010 |
Why?
|
| Platelet-Derived Growth Factor | 1 | 1991 | 26 | 0.010 |
Why?
|
| Antibodies, Monoclonal | 1 | 1993 | 329 | 0.010 |
Why?
|
| Culture Media | 1 | 1991 | 98 | 0.010 |
Why?
|
| Cell Division | 1 | 1991 | 154 | 0.010 |
Why?
|
| Uterine Cervical Neoplasms | 1 | 1993 | 297 | 0.010 |
Why?
|
| Cells, Cultured | 1 | 1993 | 985 | 0.010 |
Why?
|